Stage-associated incidence of serum circulating immune complexes in patients with untreated bronchogenic carcinoma

Ruı́z-Argüelles, Alejandro; Jett, James R.; Ritts, Roy E.

doi:10.1007/bf00199174

Cited by 6 publications

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Limitations of immune complex measurements in colorectal disease

Hobbiss

Cooper

Moore

et al. 1983

Journal of British Surgery

View full text Add to dashboard Cite

Three techniques (Clq, Raji and L1210 binding assays) alleged to measure circulating immune complexes (ICs) were applied to the sera of 101 patients with colorectal disease (54 carcinoma; 23 inflammatory; 13 benign tumour and 11 miscellaneous) at the time of diagnostic or definitive surgery, and 58 healthy adult controls. Elevated levels in the pathological sera were observed by all 3 methods in order of sensitivity: Raji greater than Clq greater than L1210. However, none of them differentiated between benign, inflammatory and neoplastic conditions nor, in the case of colorectal carcinoma, was there any correlation with stage of disease. With the exception of Raji v. L1210 (r = 0.43, P less than 0.001), correlations between the various assays were poor and levels of serum carcinoembryonic antigen (CEA) did not correlate with ICs measured by any of the techniques. Indeed, the IC assays were even less discriminatory than CEA, which was elevated mainly in the serum of carcinoma patients and which was positively correlated with serum gamma-glutamyl transpeptidase (gamma GT) (r = 0.42, P less than 0.005). The data suggest that the lack of concordance between the IC assays is a reflection of heterogeneity among ICs, interfering factors present in pathological sera, or both. Thus the IC assays deployed here have neither diagnostic nor prognostic utility in colorectal disease at this time, and immunochemical characterization of the serum reactive material detected by the different assays is required.

show abstract

Limitations of immune complex measurements in colorectal disease

Hobbiss

Cooper

Moore

et al. 1983

Journal of British Surgery

View full text Add to dashboard Cite

show abstract

Characterization of a lung‐cancer‐associated auto‐antigen

Zeng

Alpert

1992

Intl Journal of Cancer

View full text Add to dashboard Cite

An antigen, protein X (Px), was purified from immune complexes isolated from malignant pleural effusions from patients with adenocarcinoma of the lung by EDTA treatment, PEG 8000 precipitation, protein A affinity chromatography, and Sephadex G-200 separation in the presence of 3 M NaCl. The purified antigen had a M(r) 17,000 by SDS-PAGE, and consisted of isoelectric species of pI 6.3 and 6.6. Purified Px recombined with Ig isolated from pleural fluids from patients with lung adenocarcinoma, but not with Ig from patients with breast carcinoma. Using an autologous human and heterologous chicken antibody, Px was found, by immunohistology, in the cytoplasm of some of the well-differentiated lung adenocarcinoma cells, but was not seen in normal lung or a variety of other malignant tissues. A liquid-phase competitive-inhibition RIA was developed. Over 30 ng/ml of Px were found in 9 of 15 pleural fluids from patients with lung carcinoma, none of 20 from patients with breast, ovary, stomach or colon cancer, and in 3 of 15 patients with unknown primary tumor. Our data suggest that Px may be a lung-cancer-associated autoantigen which can elicit a host humoral response in vivo.

show abstract

Immunologic Methods of Diagnostic and Prognostic Value in Tumor Bearers

McCormick¹

1985

Advances in Immunity and Cancer Therapy

View full text Add to dashboard Cite

Stage-associated incidence of serum circulating immune complexes in patients with untreated bronchogenic carcinoma

Abstract: Summary. Serum

Cited by 6 publications

References 13 publications

Limitations of immune complex measurements in colorectal disease

Limitations of immune complex measurements in colorectal disease

Characterization of a lung‐cancer‐associated auto‐antigen

Immunologic Methods of Diagnostic and Prognostic Value in Tumor Bearers

Contact Info

Product

Resources

About